Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 2020;46(6):1127-53. https://www.ncbi.nlm.nih.gov/pubmed/32383061
Adamsick ML, Elshaboury RH, Gift T, Mansour MK, Kotton CN, Gandhi RG. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report. Transpl Infect Dis 2019;21(2):e13048. https://www.ncbi.nlm.nih.gov/pubmed/30636363
Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45(10):2793-7. https://www.ncbi.nlm.nih.gov/pubmed/11557471
Andes D, Kovanda L, Desai A, Kitt T, Zhao M, Walsh TJ. Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. Antimicrob Agents Chemother 2018;62(7). https://www.ncbi.nlm.nih.gov/pubmed/29735569
Asberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant 2014;18(1):103-11. https://www.ncbi.nlm.nih.gov/pubmed/24152053
Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;62(1):99-101. https://pubmed.ncbi.nlm.nih.gov/18583085/
Cartledge JD., Midgely J., Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. Journal of Clinical Pathology 1997;50(6):477. https://pubmed.ncbi.nlm.nih.gov/9378812/
Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents 2016;48(6):728-31. https://www.ncbi.nlm.nih.gov/pubmed/27769709
Chau MM, Daveson K, Alffenaar JC, Gwee A, Ho SA, Marriott DJE, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Intern Med J 2021;51 Suppl 7:37-66. https://www.ncbi.nlm.nih.gov/pubmed/34937141
Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994;97(2):135-44. https://www.ncbi.nlm.nih.gov/pubmed/8059779
Dieringer TD, Schaenman JM, Davis MR. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules. J Antimicrob Chemother 2022;77(5):1417-23. https://www.ncbi.nlm.nih.gov/pubmed/35174391
Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012;56(11):5503-10. https://www.ncbi.nlm.nih.gov/pubmed/22890761
Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56(9):4793-9. https://www.ncbi.nlm.nih.gov/pubmed/22751544
Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56(6):2806-13. https://www.ncbi.nlm.nih.gov/pubmed/22391534
Durani U, Tosh PK, Barreto JN, Estes LL, Jannetto PJ, Tande AJ. Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob Agents Chemother 2015;59(8):4914-8. https://www.ncbi.nlm.nih.gov/pubmed/26055378
Elhence H, Mongkolrattanothai K, Mohandas S, Neely MN. Isavuconazole Pharmacokinetics and Pharmacodynamics in Children. Pharmaceutics 2022;15(1). https://www.ncbi.nlm.nih.gov/pubmed/36678704
Hanai Y, Takahashi Y, Niwa T, Mayumi T, Hamada Y, Kimura T, et al. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis. J Clin Pharm Ther 2021;46(3):622-32. https://www.ncbi.nlm.nih.gov/pubmed/33547647
Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother 2017;72(10):2891-7. https://www.ncbi.nlm.nih.gov/pubmed/29091190
John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol 2019;15(11):881-95. https://www.ncbi.nlm.nih.gov/pubmed/31550939
Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother 2014;58(11):6993-5. https://www.ncbi.nlm.nih.gov/pubmed/25199774
Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 1977;11(2):244-7. https://www.ncbi.nlm.nih.gov/pubmed/848928
Krens SD, Hodiamont CJ, Juffermans NP, Mathot RAA, van Hest RM. Population Pharmacokinetics of Ganciclovir in Critically Ill Patients. Ther Drug Monit 2020;42(2):295-301. https://www.ncbi.nlm.nih.gov/pubmed/31425489
Lai T, Alffenaar JW, Kesson A, Bandodkar S, Roberts JA. Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. J Antimicrob Chemother 2020;75(3):726-9. https://www.ncbi.nlm.nih.gov/pubmed/31855264
Lau C, Marriott D, Schultz HB, Gould M, Andresen D, Wicha SG, et al. Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines. Int J Antimicrob Agents 2021;58(6):106443. https://www.ncbi.nlm.nih.gov/pubmed/34551358
Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009;49(6):928-30. https://www.ncbi.nlm.nih.gov/pubmed/19681707
Lim M, Menson E, Tong CY, Lin JP. Use of therapeutic drug monitoring in the long-term valaciclovir therapy of relapsing herpes simplex virus encephalitis in children. J Antimicrob Chemother 2009;64(6):1340-1. https://www.ncbi.nlm.nih.gov/pubmed/19828489
Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother 2016;71(7):1786-99. https://www.ncbi.nlm.nih.gov/pubmed/27165788
Luxton T, King N, Walti C, Jeuken L, Sandoe J. A systematic review of the effect of therapeutic drug monitoring on patient health outcomes during treatment with penicillins. J Antimicrob Chemother 2022;77(6):1532-41. https://www.ncbi.nlm.nih.gov/pubmed/35355067
Mahmoud SH, Shen C. Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing. Pharmaceutics 2017;9(3). https://www.ncbi.nlm.nih.gov/pubmed/28926966
Mangalore RP, Ashok A, Lee SJ, Romero L, Peel TN, Udy AA, et al. Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis et al. Clin Infect Dis 2022. https://www.ncbi.nlm.nih.gov/pubmed/35731853
Martson AG, Edwina AE, Burgerhof JGM, Berger SP, de Joode A, Damman K, et al. Ganciclovir therapeutic drug monitoring in transplant recipients. J Antimicrob Chemother 2021;76(9):2356-63. https://www.ncbi.nlm.nih.gov/pubmed/34160036
McCreary EK, Davis MR, Narayanan N, Andes DR, Cattaneo D, Christian R, et al. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy 2023;43(10):1043-50. https://www.ncbi.nlm.nih.gov/pubmed/37459118
McDonald C, Cotta MO, Little PJ, McWhinney B, Ungerer JP, Lipman J, et al. Is high-dose beta-lactam therapy associated with excessive drug toxicity in critically ill patients? Minerva Anestesiol 2016;82(9):957-65. https://www.ncbi.nlm.nih.gov/pubmed/27054905
Miceli MH, Perissinotti AJ, Kauffman CA, Couriel DR. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses 2015;58(7):432-6. https://www.ncbi.nlm.nih.gov/pubmed/26102575
Muilwijk EW, de Lange DW, Schouten JA, Wasmann RE, Ter Heine R, Burger DM, et al. Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. Antimicrob Agents Chemother 2020;64(10). https://www.ncbi.nlm.nih.gov/pubmed/32816723
Padulles A, Colom H, Bestard O, Melilli E, Sabe N, Rigo R, et al. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients. Antimicrob Agents Chemother 2016;60(4):1992-2002. https://www.ncbi.nlm.nih.gov/pubmed/26824942
Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012;55(8):1080-7. https://www.ncbi.nlm.nih.gov/pubmed/22761409
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46(2):201-11. https://www.ncbi.nlm.nih.gov/pubmed/18171251
Pham AN, Bubalo JS, Lewis JS, 2nd. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses 2016;59(4):226-33. https://www.ncbi.nlm.nih.gov/pubmed/26742659
Pouplin T, Pouplin JN, Van Toi P, Lindegardh N, Rogier van Doorn H, Hien TT, et al. Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother 2011;55(7):3624-6. https://www.ncbi.nlm.nih.gov/pubmed/21576427
Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 2011;33(3):350-4. https://www.ncbi.nlm.nih.gov/pubmed/21544017
Ramos-Martin V, Johnson A, McEntee L, Farrington N, Padmore K, Cojutti P, et al. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother 2017;72(12):3382-9. https://www.ncbi.nlm.nih.gov/pubmed/28962026
Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M, et al. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Ther Drug Monit 2020;42(1):83-92. https://www.ncbi.nlm.nih.gov/pubmed/31652190
Richter DC, Frey O, Rohr A, Roberts JA, Koberer A, Fuchs T, et al. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection 2019;47(6):1001-11. https://www.ncbi.nlm.nih.gov/pubmed/31473974
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014;14(6):498-509. https://www.ncbi.nlm.nih.gov/pubmed/24768475
Roggeveen LF, Guo T, Fleuren LM, Driessen R, Thoral P, van Hest RM, et al. Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial. Crit Care 2022;26(1):265. https://www.ncbi.nlm.nih.gov/pubmed/36064438
Sandaradura I, Marriott DJE, Day RO, Norris RLG, Pang E, Stocker SL, et al. Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. Eur J Clin Microbiol Infect Dis 2021;40(7):1521-8. https://www.ncbi.nlm.nih.gov/pubmed/33638727
Seki M, Yabuno K, Miyawaki K, Miwa Y, Tomono K. Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features. Clin Pharmacol 2012;4:71-5. https://www.ncbi.nlm.nih.gov/pubmed/23236257
Selby PR, Shakib S, Peake SL, Warner MS, Yeung D, Hahn U, et al. A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients. Clin Pharmacokinet 2021;60(6):727-39. https://www.ncbi.nlm.nih.gov/pubmed/33515202
Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35(4):707-13. https://www.ncbi.nlm.nih.gov/pubmed/1648887
Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug Metab Toxicol 2015;11(2):205-19. https://www.ncbi.nlm.nih.gov/pubmed/25428442
Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T, et al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta 2013;424:119-22. https://www.ncbi.nlm.nih.gov/pubmed/23747486
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24 Suppl 1:e1-e38. https://www.ncbi.nlm.nih.gov/pubmed/29544767
Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000;46(2):86-94. https://www.ncbi.nlm.nih.gov/pubmed/10671757
Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12. https://www.ncbi.nlm.nih.gov/pubmed/17143808
Wilson AP, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994;4 Suppl 1:1-30. https://www.ncbi.nlm.nih.gov/pubmed/18611626
Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79(11):1477-83. https://www.ncbi.nlm.nih.gov/pubmed/15940035
Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, et al. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 2013;57(12):6165-70. https://www.ncbi.nlm.nih.gov/pubmed/24080664
Yeoh DK, Moore AS, Kotecha RS, Bartlett AW, Ryan AL, Cann MP, et al. Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10-year review. Pediatr Blood Cancer 2021;68(11):e29275. https://www.ncbi.nlm.nih.gov/pubmed/34357688
